Changes in the Ratio of Tc1/Tc2 and Th1/Th2 Cells but Not in Subtypes of NK-Cells in Preeclampsia

Hu, Yali; Zhou, Jianjun; Hao, Sha; Wang, Zhi­qun; Dai, Yiming; Ling, Jiwei; Hou, Yayi

doi:10.3390/i8060492

Cited by 4 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in PBMC derived from some women with PE, Th1 cytokines expression increased and Th2 cytokines expression decreased, implying the balance shifts toward Th1-type immunity[5]–[7]. Our previous data also showed the decreased percentages of Tc2 and Th2 cells and the increased ratios of Tc1/Tc2 in both decidua and maternal peripheral blood of PE patients [8]. Moreover, the increase of Th1-type cytokine TNF-α was thought to associate with PE [9]–[12].…”

Section: Introductionmentioning

confidence: 86%

Mesenchymal Stem Cells Ameliorate Th1-Induced Pre-Eclampsia-Like Symptoms in Mice via the Suppression of TNF-α Expression

et al. 2014

Self Cite

View full text Add to dashboard Cite

Pre-eclampsia (PE) is thought to be a pregnancy-induced autoimmune disease. Despite several strategies carried out for targeting specific factors relevant to its pathogenesis, PE remains potentially fatal to some patients. Here, we reported a way to isolate mesenchymal stem cells (MSCs) from decidua. The MSCs not only exhibited differentiation and self-renewal capacities, they also possessed immunomodulatory functions and secreted some soluble mediators including IL-6, TGF-β, IDO, VEGF and COX-2. Most importantly, the MSCs were specifically provided with the ability to suppress T cells proliferation by IDO in response to inflammatory cytokine IFN-γ. Moreover, we developed a Th1 cell-induced PE mouse model which displayed a high level of pathogenesis factor TNF-α. Strikingly, MSCs-based therapy significantly ameliorated both clinical and histopathological severity of PE symptoms including decreasing the blood pressure and proteinuria, suppressing glomerulonephritis, protecting the feto-placental development. The therapy also reversed abnormal TNF-α expression in uterine and splenic lymphocytes. These data suggest that MSCs may ameliorate Th1-induced PE-like symptoms in mice via the suppression of TNF-α and MSCs-based therapy may provide a potential novel method for PE.

show abstract

Section: Introductionmentioning

confidence: 86%

Mesenchymal Stem Cells Ameliorate Th1-Induced Pre-Eclampsia-Like Symptoms in Mice via the Suppression of TNF-α Expression

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…9 The dNK or pNK cells culture medium was supplemented with various concentration of CYR61, LM609, U0126, LY294002, or DMSO (served as a control). Peripheral blood NK (pNK) cells were isolated and purified as previously described and served as controls.…”

Section: Preparation Of Dnk and Pnk Cellsmentioning

confidence: 99%

“…Peripheral blood NK (pNK) cells were isolated and purified as previously described and served as controls. 9 The dNK or pNK cells culture medium was supplemented with various concentration of CYR61, LM609, U0126, LY294002, or DMSO (served as a control).…”

Section: Preparation Of Dnk and Pnk Cellsmentioning

confidence: 99%

CYR61 Modulates the Vascular Endothelial Growth Factor C Expression of Decidual NK Cells Via PI3K/AKT Pathway

Zhang

Ding

Diao

et al. 2011

American J Rep Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Density of DCs drastically affects antigen presentation in uencing the outcome of T cell responses. The CD4 T cell pro le in PE patients is altered as the number of Th2 cells is decreased in the pre-eclamptic decidua, compared to normal pregnancy associated decidua [19]. Along these lines, the ability of DCs to induce regulatory T cells is impaired in PE patients [20], disrupting the tolerogenic environment characteristic of a normal pregnancy.…”

Section: Introductionmentioning

confidence: 99%

Pilot study protocol for determining differences in quantitative and functional aspects of dendritic cell subsets in early onset pre-eclampsia patients- a feasibility study for identification of biomarker(s) and immunotherapeutic target(s)

Sundararajan

Vora

Natesan

2020

Preprint

View full text Add to dashboard Cite

Background: Pre-eclampsia (PE) is a pregnancy associated pro-inflammatory disorder. The only known treatment is to deliver the placenta and fetus. PE is clinically identified by hypertension and proteinuria post-20th week of gestation. Early onset pre-eclampsia (EOPE), a severe form of PE is defined as when the clinical symptoms are observed before 34 weeks of gestation. There are no definite biomarkers available for early diagnosis of EOPE. Human dendritic cell (DC) subsets (CD1c+, CD141+ myeloid DCs and plasmacytoid DCs) are intricately involved with the process of inflammation and are significantly altered (quantitatively and functionally) in several proinflammatory disorders. These changes offer value for monitoring DC subsets as potential biomarker(s) and as targets for immunotherapeutic treatment. DC subsets play a critical role in normal pregnancy by mediating efficient migration and invasion of trophoblasts and maintaining anti-inflammatory environment of immunotolerance. In contrast, the status of DC subsets in the proinflammatory microenvironment of EOPE pregnancy requires thorough evaluation. In this direction, the designed study protocol aims to understand how DC subsets are altered (quantitatively and functionally) in EOPE patients, compared to normal pregnant women. Methods: Study protocol is designed to determine changes in the profile of DC subsets in the blood and decidua of EOPE patients by multiparametric flow cytometry approach. Normal pregnant women are included as controls.Discussion: Human DC subsets are altered both quantitatively and functionally in the pro-inflammatory microenvironment. EOPE is a pro-inflammatory disorder and changes in the composition and function of DC subsets in these patients, compared to normal pregnant women is unclear. In this study, the blood sample-based analysis will determine the feasibility for identification of DC subsets associated novel immune biomarkers for early diagnosis of EOPE. In addition, changes in the profile of DC subsets in the decidua of EOPE patients will determine the feasibility for developing novel immunotherapeutic strategies targeting distinct DC subsets or their products for the treatment of EOPE. Overall, the current study protocol and findings will help develop future large scale, prospective design clinical trials focussing on formulating strategies for early diagnosis and treatment of EOPE among pregnant women.

show abstract

Changes in the Ratio of Tc1/Tc2 and Th1/Th2 Cells but Not in Subtypes of NK-Cells in Preeclampsia

Cited by 4 publications

References 28 publications

Mesenchymal Stem Cells Ameliorate Th1-Induced Pre-Eclampsia-Like Symptoms in Mice via the Suppression of TNF-α Expression

Mesenchymal Stem Cells Ameliorate Th1-Induced Pre-Eclampsia-Like Symptoms in Mice via the Suppression of TNF-α Expression

CYR61 Modulates the Vascular Endothelial Growth Factor C Expression of Decidual NK Cells Via PI3K/AKT Pathway

Pilot study protocol for determining differences in quantitative and functional aspects of dendritic cell subsets in early onset pre-eclampsia patients- a feasibility study for identification of biomarker(s) and immunotherapeutic target(s)

Contact Info

Product

Resources

About